Description
This assay uses the Luminex® 200™ platform.
Consider this assay for precise analysis of amyloid beta and tau proteins in cerebrospinal fluid (CSF) samples. The Human Amyloid Beta and Tau 4-Plex Discovery Assay® Array measures critical biomarkers related to Alzheimer’s disease and other neurodegenerative disorders.
Ideal for research on Alzheimer’s disease and tauopathies, this assay provides insights into the roles of Aβ40, Aβ42, and tau proteins in neurodegeneration and cognitive decline. For example, elevated levels of pTau 181 are associated with tau pathology in Alzheimer’s.
Optimized for CSF samples, this assay supports research into disease mechanisms and progression, aiding in the identification of biomarkers for early diagnosis and monitoring of neurodegenerative diseases.
! For even more delicate concentration trends, such as those in the femtogram range, or when working with very limited sample volumes and picogram-level expectations, consider our Human MSD® Discovery Assay® Neurology 3-Plex Panel 1 (MSDN3) and Human MSD® Discovery Assay® pTau217 (MSDPTAU217). These arrays offer the highest sensitivity available for precise and accurate measurement of biomarkers associated with neurological and neurodegenerative diseases.
Discover the power of precision with our The Human Amyloid Beta and Tau 4-Plex Discovery Assay® Array , expertly designed for the Luminex® 200™ platform. This cutting-edge technology enables the simultaneous detection of multiple biomarkers from a minimal single sample, delivering comprehensive insights with unmatched efficiency. Streamline your research and unlock a new level of detail with our advanced multiplex assay solution.
Click here for information on shipping biological samples for Discovery Assays